Global Registrational Phase 3 ZUPREME Program Evaluating Petrelintide in Overweight or Obesity Initiated – Zealand Pharma
Zealand Pharma A/S announces the initiation of the global registrational Phase 3 Zupreme program, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with overweight… read more.
